Stealth BioTherapeutics Secures Grant for Mitochondrial Disease Research Breakthrough
Stealth BioTherapeutics Advances Mitochondrial Disease Research with New Grant
In an exciting development for mitochondrial medicine, Stealth BioTherapeutics, a biotechnology firm at the forefront of mitochondrial research, has announced the receipt of a grant from the UK Research and Innovation Medical Research Council (MRC). This funding is designated to support an innovative preclinical exploration of its leading compound, SBT-589, specifically targeting Leigh syndrome, a devastating disorder caused by mitochondrial dysfunction affecting energy supply in critical areas like the brain and muscles.
The collaborative project features key players from various scientific frameworks including the Mary Lyon Centre at MRC Harwell, the MRC National Mouse Genetics Network (NMGN), and prominent academic figures from University College London (UCL). The goal is to assess the compound’s efficacy in enhancing survival rates, improving motor functions, and monitoring biomarkers in a mouse model of Leigh syndrome, a significant step towards practical applications of this research.
Previous studies indicate that SBT-589 has yielded promising results in patient-derived cells and across various animal models, demonstrating a significant improvement in bioenergetics. Such findings underscore the therapeutic potential of SBT-589 in combating the progressive nature of Leigh syndrome and related disorders.
Professor Robert Pitceathly of UCL, who is involved in this multi-institutional collaboration, expressed enthusiasm about leveraging the NMGN MitoCluster platform at MRC Harwell. His statement highlighted the project's importance in systematically characterizing mitochondrial dysfunction and its implications in disease, thus potentially paving the way for accelerated therapeutic development.
David A. Brown, Ph.D., Chief Scientific Officer of Stealth BioTherapeutics, emphasized that the project supports the company's long-standing dedication to the mitochondrial research community. He acknowledged that the preclinical evaluation of promising compounds like SBT-589 had historically faced hurdles, which this initiative aims to effectively address. The goal is to bridge gaps between innovative scientific discoveries and clinical therapies that can significantly impact patient lives.
The MRC Business Engagement Fund’s mission is to create synergies between industry players and the global research community, with an emphasis on translating scientific innovations into effective patient care solutions. Professor Owen Sansom, Director of the MRC National Mouse Genetics Network, reiterated the fund's role in fostering early-stage collaborations and underlined the urgency in developing new methodologies for understanding and treating mitochondrial diseases.
As this partnership solidifies, the implications for those dealing with mitochondrial dysfunction are profound. There exists a pressing need for effective treatments in this space, and Stealth BioTherapeutics is poised to lead the charge in addressing these unmet medical needs.
About Stealth BioTherapeutics
Stealth BioTherapeutics is dedicated to revolutionizing medical care for patients with diseases linked to mitochondrial dysfunction. Their ongoing research continues to yield substantial advancements in treatment options, including elamipretide, which received accelerated approval from the FDA in 2025. As the company charts its path forward, it aims to introduce more cutting-edge solutions, including its next-in-class candidate, bevemipretide, focusing on a wider array of neurological and ophthalmic conditions.
About the Mary Lyon Centre at MRC Harwell
The Mary Lyon Centre serves as the UK's cornerstone for mouse genetics, facilitating preclinical models that are crucial in human disease studies. Located in a hub for research innovation, it collaborates extensively with various clusters to optimize resources and foster transformative scientific dialogues.
About the MRC National Mouse Genetics Network
Founded to enhance foundational research, the MRC National Mouse Genetics Network unites premier institutions in the UK. The initiative focuses on demystifying the genetic and molecular complexities of diseases, utilizing advanced mouse models to foster groundbreaking medical solutions.
With this grant, Stealth BioTherapeutics is not just aiming to advance medical science; it has embarked on a mission to change lives, one innovation at a time.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.